Assessment cycle 2023 Q1 — page 2
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity randomising 248 participants over 24 weeks. Primary result: Mean change up to −15.4 %…
Moderate22 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity randomising 605 participants over 32 weeks. Primary result: Dose-dependent weight…
31 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes randomising 411 participants over 16 weeks. Primary result: Glycaemic…
07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity randomising 3,731 participants over 56 weeks. Primary result: Mean change −8.0 %…
High18 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity randomising 2,254 participants over 160 weeks. Primary result…
Moderate17 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in sleep apnoea and obesity randomising 359 participants over 32 weeks. Primary result…
Moderate20 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in adolescent obesity randomising 251 participants over 56 weeks. Primary result: Estimated…
Moderate23 Nov 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes randomising 9,340 participants over median 3.8 years…
High28 Dec 2023 -
Randomised, open-label, active-controlled, phase 3 study of Liraglutide in type 2 diabetes randomising 464 participants over 26 weeks. Primary result: Difference −0.33…
High18 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) randomising 1,398 participants over 52 weeks. Primary result…
Moderate10 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) randomising 835 participants over 26 weeks. Primary result…
Moderate07 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash randomising 52 participants over 48 weeks. Primary result: Resolution in 39 % versus 9…
Low12 Apr 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 976 participants over 26 weeks. Primary result: Superior to…
High15 Aug 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,098 participants over 52 weeks. Primary result: Superior to…
High04 May 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 599 participants over 26 weeks. Primary result: Non-inferior to…
High07 Oct 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease randomising 576 participants over 52 weeks. Primary…
Low20 Apr 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,842 participants over 36 weeks. Primary result: Dose-dependent…
High23 Feb 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes randomising 9,901 participants over median 5.4 years…
High20 Feb 2024 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 295 participants over 30 weeks. Primary result: Superior glycaemic…
High24 Jul 2023 -
Randomised, open-label, active-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 911 participants over 26 weeks. Primary result: Did not meet…
High08 Jul 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Exenatide in cardiovascular and type 2 diabetes randomising 14,752 participants over median 3.2 years…
High16 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 680 participants over 24 weeks. Primary result: Reduction of…
High09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 495 participants over 24 weeks. Primary result: Reduction of…
High16 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 446 participants over 24 weeks. Primary result: Additional…
High29 Sep 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Lixisenatide in cardiovascular and type 2 diabetes randomising 6,068 participants over median 25 months…
High21 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes randomising 377 participants over 30 weeks. Primary result: Reduction of…
High28 Jun 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes randomising 4,076 participants…
Moderate21 Feb 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes randomising 9,463 participants over median 1.6 years…
Moderate22 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Exenatide in cardiovascular randomising 91 participants over 6 months. Primary result: No significant…
Moderate04 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 412 participants over 26 weeks. Primary result: Mean change −15.2…
Moderate15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 404 participants over 26 weeks. Primary result: Directionally…
Moderate08 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash randomising 61 participants over 12 months. Primary result: Reduction in hepatic fat…
Low18 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gh axis over single dose. Primary result: Dose-dependent growth-hormone release without a measurable rise in…
Low05 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over in-hospital. Primary result: The programme did not proceed. The…
02 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis randomising Fewer than 100 participants over up to 49 days. Primary result: Sustained elevation of…
Low16 Oct 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over multiple weekly doses. Primary result: Cumulative elevation of insulin-like growth factor 1 with…
Low13 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over single dose. Primary result: Marked growth-hormone release with attenuation on repeated administration.
Low09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over 16 weeks. Primary result: Tachyphylaxis of the growth-hormone…
Low20 Nov 2023 -
Diagnostic accuracy, phase 3 study of GHRP-2 in gh axis over single test. Primary result: Approved in Japan as a diagnostic stimulation agent. The Institute records that…
Moderate02 Aug 2023 -
Phase 1 ascending dose, phase 1 study of GHRP-6 in gh axis over single dose. Primary result: Dose-dependent growth-hormone release with a marked orexigenic effect.
Low29 May 2023
page 2 of 13